vs

Side-by-side financial comparison of Globe Life (GL) and Steris (STE). Click either name above to swap in a different company.

Globe Life is the larger business by last-quarter revenue ($1.6B vs $1.5B, roughly 1.0× Steris). Globe Life runs the higher net margin — 17.3% vs 12.9%, a 4.5% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs 5.3%). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 4.1%).

Globe Life Inc. (GL) is an American financial services holding company listed on the New York Stock Exchange which operates through its wholly owned subsidiaries providing life insurance, annuity, and supplemental health insurance products. The company is based in McKinney, Texas.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

GL vs STE — Head-to-Head

Bigger by revenue
GL
GL
1.0× larger
GL
$1.6B
$1.5B
STE
Growing faster (revenue YoY)
STE
STE
+3.8% gap
STE
9.2%
5.3%
GL
Higher net margin
GL
GL
4.5% more per $
GL
17.3%
12.9%
STE
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
4.1%
GL

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
GL
GL
STE
STE
Revenue
$1.6B
$1.5B
Net Profit
$270.5M
$192.9M
Gross Margin
43.8%
Operating Margin
18.3%
Net Margin
17.3%
12.9%
Revenue YoY
5.3%
9.2%
Net Profit YoY
11.2%
EPS (diluted)
$3.39
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GL
GL
STE
STE
Q1 26
$1.6B
Q4 25
$1.5B
$1.5B
Q3 25
$1.5B
$1.5B
Q2 25
$1.5B
$1.4B
Q1 25
$1.5B
$1.5B
Q4 24
$1.5B
$1.4B
Q3 24
$1.5B
$1.3B
Q2 24
$1.4B
$1.3B
Net Profit
GL
GL
STE
STE
Q1 26
$270.5M
Q4 25
$266.1M
$192.9M
Q3 25
$387.8M
$191.9M
Q2 25
$252.7M
$177.4M
Q1 25
$254.6M
$145.7M
Q4 24
$255.2M
$173.5M
Q3 24
$303.0M
$150.0M
Q2 24
$258.4M
$145.4M
Gross Margin
GL
GL
STE
STE
Q1 26
Q4 25
43.8%
Q3 25
44.2%
Q2 25
45.1%
Q1 25
43.3%
Q4 24
44.5%
Q3 24
26.1%
43.6%
Q2 24
23.3%
44.7%
Operating Margin
GL
GL
STE
STE
Q1 26
Q4 25
21.7%
18.3%
Q3 25
31.5%
18.2%
Q2 25
21.2%
17.7%
Q1 25
21.4%
14.6%
Q4 24
21.3%
17.9%
Q3 24
26.3%
16.5%
Q2 24
23.5%
14.5%
Net Margin
GL
GL
STE
STE
Q1 26
17.3%
Q4 25
17.5%
12.9%
Q3 25
25.6%
13.1%
Q2 25
17.1%
12.8%
Q1 25
17.2%
9.8%
Q4 24
17.4%
12.7%
Q3 24
20.8%
11.3%
Q2 24
17.9%
11.4%
EPS (diluted)
GL
GL
STE
STE
Q1 26
$3.39
Q4 25
$3.28
$1.96
Q3 25
$4.73
$1.94
Q2 25
$3.05
$1.79
Q1 25
$3.01
$1.48
Q4 24
$3.00
$1.75
Q3 24
$3.44
$1.51
Q2 24
$2.83
$1.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GL
GL
STE
STE
Cash + ST InvestmentsLiquidity on hand
$183.8M
$423.7M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$6.1B
$7.2B
Total Assets
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GL
GL
STE
STE
Q1 26
$183.8M
Q4 25
$314.7M
$423.7M
Q3 25
$62.8M
$319.2M
Q2 25
$116.7M
$279.7M
Q1 25
$134.1M
$171.7M
Q4 24
$85.0M
$155.2M
Q3 24
$100.5M
$172.2M
Q2 24
$100.6M
$198.3M
Total Debt
GL
GL
STE
STE
Q1 26
Q4 25
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Stockholders' Equity
GL
GL
STE
STE
Q1 26
$6.1B
Q4 25
$6.0B
$7.2B
Q3 25
$5.7B
$7.0B
Q2 25
$5.4B
$7.0B
Q1 25
$5.4B
$6.6B
Q4 24
$5.3B
$6.4B
Q3 24
$4.6B
$6.6B
Q2 24
$5.2B
$6.4B
Total Assets
GL
GL
STE
STE
Q1 26
Q4 25
$30.8B
$10.6B
Q3 25
$30.5B
$10.4B
Q2 25
$29.8B
$10.4B
Q1 25
$29.7B
$10.1B
Q4 24
$29.1B
$10.0B
Q3 24
$29.6B
$10.2B
Q2 24
$28.3B
$10.1B
Debt / Equity
GL
GL
STE
STE
Q1 26
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GL
GL
STE
STE
Operating Cash FlowLast quarter
$298.2M
Free Cash FlowOCF − Capex
$199.5M
FCF MarginFCF / Revenue
13.3%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GL
GL
STE
STE
Q1 26
Q4 25
$350.6M
$298.2M
Q3 25
$306.0M
$287.8M
Q2 25
$307.9M
$420.0M
Q1 25
$431.9M
$260.8M
Q4 24
$336.9M
$332.8M
Q3 24
$340.6M
$250.7M
Q2 24
$374.1M
$303.7M
Free Cash Flow
GL
GL
STE
STE
Q1 26
Q4 25
$330.1M
$199.5M
Q3 25
$208.7M
$201.3M
Q2 25
$295.0M
$326.4M
Q1 25
$420.1M
$189.9M
Q4 24
$321.9M
$243.6M
Q3 24
$311.3M
$148.8M
Q2 24
$356.5M
$195.7M
FCF Margin
GL
GL
STE
STE
Q1 26
Q4 25
21.7%
13.3%
Q3 25
13.8%
13.8%
Q2 25
19.9%
23.5%
Q1 25
28.4%
12.8%
Q4 24
22.0%
17.8%
Q3 24
21.4%
11.2%
Q2 24
24.8%
15.3%
Capex Intensity
GL
GL
STE
STE
Q1 26
Q4 25
1.3%
6.6%
Q3 25
6.4%
5.9%
Q2 25
0.9%
6.7%
Q1 25
0.8%
4.8%
Q4 24
1.0%
6.5%
Q3 24
2.0%
7.7%
Q2 24
1.2%
8.4%
Cash Conversion
GL
GL
STE
STE
Q1 26
Q4 25
1.32×
1.55×
Q3 25
0.79×
1.50×
Q2 25
1.22×
2.37×
Q1 25
1.70×
1.79×
Q4 24
1.32×
1.92×
Q3 24
1.12×
1.67×
Q2 24
1.45×
2.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GL
GL

Life premium$853.2M55%
Health premium$416.9M27%
Other$289.5M19%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons